Sandy Spring Bank’s Pacific Biosciences PACB Stock Holding History

Sandy Spring Bank’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$461	Buy	390 +90	+30%	+$138	﹤0.01%	1133
2024 Q4	$549	Hold	300	–	–	﹤0.01%	1131
2024 Q3	$510	Hold	300	–	–	﹤0.01%	1121
2024 Q2	$411	Hold	300	–	–	﹤0.01%	1190
2024 Q1	$1.13K	Hold	300	–	–	﹤0.01%	1105
2023 Q4	$2.94K	Sell	300 -50	-14%	-$409	﹤0.01%	979
2023 Q3	$2.92K	Sell	350 -450	-56%	-$5.14K	﹤0.01%	995
2023 Q2	$10.6K	Sell	800 -199	-20%	-$2.42K	﹤0.01%	826
2023 Q1	$11.6K	Hold	999	–	–	﹤0.01%	793
2022 Q4	$8.17K	Hold	999	–	–	﹤0.01%	852
2022 Q3	$6K	Buy	999 +588	+143%	+$3.37K	﹤0.01%	895
2022 Q2	$2K	Buy	411 +111	+37%	+$674	﹤0.01%	1058
2022 Q1	$3K	Buy	300 +200	+200%	+$2.3K	﹤0.01%	1029
2021 Q4	$2K	Hold	100	–	–	﹤0.01%	1143
2021 Q3	$3K	Hold	100	–	–	﹤0.01%	1032
2021 Q2	$3K	Buy	+100	New	+$2.91K	﹤0.01%	1045
2021 Q1	–	Sell	-280	Closed	-$7K	–	1023
2020 Q4	$7K	Buy	+280	New	+$4.76K	﹤0.01%	797

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sandy Spring Bank's PACB Position: Q1 2025 in Review

Sandy Spring Bank increased its Pacific Biosciences (PACB) stake by 30% in Q1 2025, buying an estimated $138 and bringing the position to 390 shares worth $461. The position accounts for ﹤0.01% of the portfolio, ranked #1133.

Sandy Spring Bank first reported a position in PACB in Q4 2020 and has held it in 17 quarters since. The position peaked at $11.6K in Q1 2023. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Sandy Spring Bank held 390 shares of Pacific Biosciences worth $461 as of Q1 2025.
Sandy Spring Bank bought 90 Pacific Biosciences shares in Q1 2025, an estimated $138.
Pacific Biosciences made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1133 holding.
Sandy Spring Bank first reported a position in Pacific Biosciences in Q4 2020 and has held it in 17 quarters since.
Sandy Spring Bank's Pacific Biosciences position peaked at $11.6K in Q1 2023.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.